Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
3.685 USD | +1.80% | +12.92% | +107.34% |
May. 14 | Taysha Gene Therapies Q1 Net Loss Narrows, Revenue Declines -- Shares Down After Hours | MT |
May. 14 | Transcript : Taysha Gene Therapies, Inc., Q1 2024 Earnings Call, May 14, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+107.34% | 677M | |
+45.65% | 56.65B | |
-6.88% | 39.44B | |
+39.19% | 39.03B | |
-6.65% | 26.86B | |
+12.61% | 26.75B | |
-21.34% | 19.03B | |
+0.84% | 12.28B | |
+24.14% | 12.26B | |
+27.28% | 12.04B |
- Stock Market
- Equities
- TSHA Stock
- News Taysha Gene Therapies, Inc.
- Chardan Adjusts Taysha Gene Therapies' Price Target to $6 From $16, Keeps Buy Rating